Tuesday, 26 November 2013

FOREIGN DRUG MAKERS WON 77% OF ALL PATENTS IN LAST THREE YEARS IN INDIA

Well this may not seem alarming but I think it is alarming more than two third of the pharmaceutical patents awarded by India in the last three years were granted to foreign drug maker such as Pfizer Ins , Novartis AG and F Hoffman La Roche Ltd ,which have been critical of India's intellectual property rights regime. The country issued 1,001 drug patents between April 2010 and march 2013 , of which 771 were given to foreign drug makers,mainly from the US and Europe , according to data released last week by the Indian patent office .

US insulin maker and biotech researcher Eli Lilly and co. won the most number of those patents in  that period ,securing 36 of them ,mainly for biological products and compounds to treat diabetes and related diseases. Eli Lilly was followed by Pfizer, the worlds largest drug maker ,with 32 patents and Switzerland based F Hoffmann-La Roche and Novartis with 22 and 14 patents , respectively . French drug maker Sanofi SA and Germany's Bayer AG ,too were  granted atleast a dozen Indian patents in three years.

IPO data also reveal that from April 2005 to march 2010, the patent office granted 3,488 drug patents of which more than 3000  were granted to foreign pharma companies the patents , which cover inventions related to single molecules or groups of compounds or processes leading to development of various medicine typically allow these companies exclusive marketing rights for such products for at least 15-20 years in India. 

The IPO data for 2010-13 also showed  that local drug makers and research institution were granted 230 patents. the names include Cadila healthcare Ltd, Ranbaxy laboratories ltd , Glenmark Pharmaceutical Ltd, Wockhardt Ltd and the state -run council of scientific and Industrial Research . India , which follows a stricter patent regime than the US and European Union ,has been at receiving end of criticism for turning down several patent application and revoking existing patents following judicial challenges filed  by local as well as foreign rivals. The country's patent law , unlike that of the US  and Europe doesn't allow patent grants for drugs invented before 1995 the cut off year fixed when India reintroduced its products patent ... the reasoning was that previous invention are already in the public domain and do not deserve a patent grant 

well even after this success Pfizer , in a may testimony to the US congress , alleged that India lacks a conducive business environment mainly because of its poor IPR regime .................

This reports shows a mirror to Indian drug research and development we really lack a proper research facility and as for foreign companies the are making most of this...............................................